Last reviewed · How we verify

Influenza vaccine GSK2604409A

GlaxoSmithKline · Phase 3 active Biologic

Influenza vaccine GSK2604409A is a Vaccine Biologic drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Influenza prevention.

GSK2604409A is an investigational influenza vaccine designed to stimulate immune responses against influenza virus strains.

GSK2604409A is an investigational influenza vaccine designed to stimulate immune responses against influenza virus strains. Used for Influenza prevention.

At a glance

Generic nameInfluenza vaccine GSK2604409A
SponsorGlaxoSmithKline
Drug classVaccine
ModalityBiologic
Therapeutic areaImmunology
PhasePhase 3

Mechanism of action

As an influenza vaccine candidate, GSK2604409A works by presenting viral antigens to the immune system to generate protective antibody and T-cell responses against influenza infection. The specific formulation and adjuvant strategy employed by GSK aim to enhance immunogenicity and potentially broaden protection across multiple influenza strains or improve efficacy in specific populations.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Influenza vaccine GSK2604409A

What is Influenza vaccine GSK2604409A?

Influenza vaccine GSK2604409A is a Vaccine drug developed by GlaxoSmithKline, indicated for Influenza prevention.

How does Influenza vaccine GSK2604409A work?

GSK2604409A is an investigational influenza vaccine designed to stimulate immune responses against influenza virus strains.

What is Influenza vaccine GSK2604409A used for?

Influenza vaccine GSK2604409A is indicated for Influenza prevention.

Who makes Influenza vaccine GSK2604409A?

Influenza vaccine GSK2604409A is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).

What drug class is Influenza vaccine GSK2604409A in?

Influenza vaccine GSK2604409A belongs to the Vaccine class. See all Vaccine drugs at /class/vaccine.

What development phase is Influenza vaccine GSK2604409A in?

Influenza vaccine GSK2604409A is in Phase 3.

What are the side effects of Influenza vaccine GSK2604409A?

Common side effects of Influenza vaccine GSK2604409A include Injection site reactions (pain, erythema, swelling), Systemic reactions (fever, myalgia, fatigue).

Related